Abstract:Background: Endogenous insulin supplementation is essential for individuals with type 1 diabetes (T1D). However, current treatments, including pancreas transplantation, insulin injections, and oral medications, have significant limitations. The development of engineered cells that can secrete endogenous insulin offers a promising new therapeutic strategy for type 1 diabetes (T1D). This approach could potentially circumvent autoimmune responses associated with the transplantation of differentiated β-cells or systemic delivery of viral vectors. Methods: We utilized CRISPR/Cas9 gene editing coupled with homology-directed repair (HDR) to precisely integrate a promoter-free EMCVIRES-insulin cassette into the 3' untranslated region (UTR) of the GAPDH gene in human HEK-293T cells. Subsequently quantified insulin expression levels in these engineered cells, the viability and functionality of the engineered cells when seeded on different cell vectors (GelMA and Cytopore I) were also assessed. Finally, we investigated the therapeutic potential of EMCVIRES-based insulin secretion circuits in reversing Hyperglycaemia in T1D mice. Result: Our results demonstrate that HDR-mediated gene editing successfully integrated the IRES-insulin loop into the genome of HEK-293T cells, a non-endocrine cell line, enabling the expression of human-derived insulin. Furthermore, Cytopore I microcarriers facilitated cell attachment and proliferation during in vitro culture and enhanced cell survival post-transplantation. Transplantation of these cell-laden microcarriers into mice led to the development of a stable, fat-encapsulated structure. This structure exhibited the expression of the platelet-endothelial cell adhesion molecule CD31, and no significant immune rejection was observed throughout the experiment. Diabetic mice that received the cell carriers reversed hyperglycemia, and blood glucose fluctuations under simulated feeding stimuli were very similar to those of healthy mice. Conclusion: In summary, our study demonstrates that Cytopore I microcarriers are biocompatible and promote long-term cell survival in vivo. The promoter-free EMCVIRES-insulin loop enables non-endocrine cells to secrete mature insulin, leading to a rapid reduction in glucose levels. We have presented a novel promoter-free genetic engineering strategy for insulin secretion and proposed an efficient cell transplantation method. Our findings suggest the potential to expand the range of cell sources available for the treatment of diabetes, offering new avenues for therapeutic interventions.

The Reversal of Hyperglycaemia in Diabetic Mice Using Plga Scaffolds Seeded with Islet-Like Cells Derived from Human Embryonic Stem Cells

In Vitro Expansion of Pancreatic Islet Clusters Facilitated by Hormones and Chemicals.

Scaffold-supported Transplantation of Islets in the Epididymal Fat Pad of Diabetic Mice

Small Molecules Facilitate the Reprogramming of Mouse Fibroblasts into Pancreatic Lineages

In vitro derivation of functional insulin-producing cells from human embryonic stem cells

3D printed VEGF-CPO biomaterial scaffold to promote subcutaneous vascularization and survival of transplanted islets for the treatment of diabetes

Directed differentiation of human embryonic stem cells towards a pancreatic cell fate

Reversal of Hyperglycemia by Subcutaneous Islet Engraftment Using an Atelocollagen Sponge as a Scaffold

Biomimetic Hydrogels Promote Pseudoislet Formation to Improve Glycemic Control in Diabetic Mice

Islet cell spheroids produced by a thermally sensitive scaffold: a new diabetes treatment

Encapsulated pancreatic progenitors derived from human embryonic stem cells as a therapy for insulin-dependent diabetes

Biomimetic Artificial Islet Model with Vascularized Microcapsule Structures for Durable Glycemic Control

Regulation of Blood Glucose Using Islets Encapsulated in a Melanin-Modified Immune-Shielding Hydrogel

Human amniotic mesenchymal stem cell-islet organoids enhance the efficiency of islet engraftment in a mouse diabetes model

Evaluation of Islets Derived from Human Fetal Pancreatic Progenitor Cells in Diabetes Treatment

Engineered IRES-mediated promoter-free insulin-producing cells reverse hyperglycemia

A bilaminated decellularized scaffold for islet transplantation: Structure, properties and functions in diabetic mice

Reversal of Hyperglycemia in Diabetic Rats by Portal Vein Transplantation of Islet-Like Cells Generated from Bone Marrow Mesenchymal Stem Cells.

Forward programming of hiPSCs towards beta-like cells using Ngn3, Pdx1, and MafA

Exocrine pancreas regeneration modifies original pancreas to alleviate diabetes in mouse models

Generation of Insulin-Producing Cells from PDX-1 Gene-Modified Human Mesenchymal Stem Cells.